作者: Tadayuki Kou , Masashi Kanai , Shigemi Matsumoto , Yasushi Okuno , Manabu Muto
DOI: 10.1093/JJCO/HYW018
关键词: Cancer genome sequencing 、 Whole genome sequencing 、 Precision medicine 、 Exome sequencing 、 Medicine 、 Bioinformatics 、 Genomics 、 Personal genomics 、 Targeted therapy 、 Single cell sequencing
摘要: Comprehensive genomic profiling using next-generation sequencing technologies provides insights into understanding the architecture of human cancer. This new cancer genome allows us to identify many more alterations occurring within tumors than before, some which could be potential therapeutic targets through molecular targeted agents. Currently, a large number agents are being developed, and consequently, treatment is rapidly shifting from empiric therapy employing cytotoxic anticancer drugs genotype-directed In current daily clinical practice, hotspot-based single-gene assays that detect RAS mutations in colorectal or EGFR non-small cell lung widely used variants. However, it becoming evident comprehensive analysis crucial identifying patient population may benefit accelerated development novel for early trials. For these purposes, an increasing gene panel-based commercially available practice companies. Despite several challenges implementing this approach, identification actionable likely become one standard options management near future. The use has usher era precision medicine diagnosis treatment. review, we discuss application oncology address its implementation.